PuraPharm Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

The latest announcement is out from PuraPharm Corp. Ltd. ( (HK:1498) ).

PuraPharm Corporation Limited has scheduled a board meeting for 25 March 2026 to review and approve the group’s audited annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider the publication of the annual results announcement and decide whether to recommend a final dividend, a move that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.

The most recent analyst rating on (HK:1498) stock is a Sell with a HK$0.33 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a Hong Kong-listed company engaged in the research, development, manufacturing and sale of its products, with operations conducted through a group structure of subsidiaries. The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard corporate governance framework for a listed issuer.

Average Trading Volume: 318,714

Technical Sentiment Signal: Sell

Current Market Cap: HK$173.9M

For detailed information about 1498 stock, go to TipRanks’ Stock Analysis page.